Navigation Links
AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
Date:2/23/2009

LONDON, Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma did not meet its co-primary endpoints: asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated when compared with placebo.

AstraZeneca (NYSE: AZN) will work with MAP Pharmaceuticals to conduct further analyses of these data to determine appropriate next steps for the program.

AstraZeneca and MAP Pharmaceuticals have a collaboration agreement to develop and commercialize UDB.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
5. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
6. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
7. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
10. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
11. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...25/PRNewswire/--AMPACFineChemicalsLLC(AFC),asubsid...ouncedtodaythatitreceivedtheEnvironmentalResponsib...ironmentalSummit,sponsoredbytheCaliforniaManufactu...vironmentalAssociation(IEA)andtheChemicalIndustryC...stprestigiousawardavailablefromallthreeorganizatio...
(Date:11/25/2009).../--Reportlinker.comannouncesthatanewmarketresearch...esDentalDevicesMarketAnalysisandForecaststo2015 ,...States-Dental-Devices-Market-Analysis-and-Forecast...ketAnalysisandForecaststo2015 ,, Summary ,...ionanddatarelatingtotheUSdentaldevicesmarket.Itals...
(Date:11/25/2009).../PRNewswire/--SwissrayInternational,Inc.aleadingma...,announcedtodaythatitsoperationshavebeenacquiredby...ngSwissray,smedicalimagingbrand.Theacquisitionincl...actsandinventory.After25yearsofsuccessandgrowthSwi...ladvancementswithstableandsteadygrowth. ,, "Swi...
Breaking Medicine Technology:AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Swissray International Announces New Ownership 2Information You Can Use if You Have High Blood Pressure 3A TOPROL XL 28R 29 and its Generic Equivalent Metoprolol Succinate 5742 1Information You Can Use if You Have High Blood Pressure 3A TOPROL XL 28R 29 and its Generic Equivalent Metoprolol Succinate 5742 2Information You Can Use if You Have High Blood Pressure 3A TOPROL XL 28R 29 and its Generic Equivalent Metoprolol Succinate 5742 3Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10 2009 5737 1Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10 2009 5737 2World interest in Australian fishery impact test 10539 1World interest in Australian fishery impact test 10539 2
... Ellman International launches next-generation aes...N.Y., May 18 Ellman International, Inc. announced... has granted clearance to Pelleve(TM), a skin tigh...ld to moderate facial wrinkles and rhytids for ski... on clinical data demonstrating that a single trea...
... CAMBRIDGE, Mass., May 18 Biopure Corporation ... and Drug Administration has advised the U.S. Nava... may not initiate a clinical trial of Biopure,s ox...-- 250 (bovine)] under a proposed protocol submitt...ced, the study, "Restore Effective Survival in Sho...
Other Medicine Technology:Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles 2Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles 3U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold 2U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold 3
(Date:11/25/2009)...n and treatment clinics to resume Monday, Nov. 30 ...ber 25, 2009 -- Centegra Health System is continui...hots at four Centegra Primary Care (CPC) vaccinati...rrived. The clinics are at CPC sites in Huntley, W...n as follows: ,   From 4:30 to 7:30 p....
(Date:11/25/2009)...- MISSIONSkincare ®isproudtosupportGNC,seffor...annualSt.Jude ThanksandGiving campaign,$1fromthepu...(TM)LipBalm willbedonatedtoSt.Jude.Additionally,GN...ionatcheckoutatoneoftheir5,000+retaillocationsorat...duringtheir2009 ThanksandGiving campaign. ,, "W...
(Date:11/25/2009)...ancer also can reverse a rare stomach disorder and...isease, researchers at Vanderbilt University Medic...auses thickening of the stomach lining, severe abd...a and swelling in the feet and ankles due to prote...c cancer. Previously, the only effective treatment...
(Date:11/25/2009)...e Imaging Services, known as one of the largest in...ng equipment, now offering a total solution for di...ervice and installation with acquisition of Kosmic...California) , Brick, NJ (...vices is proud to announce its acquisition of Kosm...
(Date:11/25/2009)...ordsSafely,ImproveCare ,, WASHINGTON,Nov.25/P...irs(VA)andKaiserPermanentetodayannouncedanexciting...,sheroes.VAandKaiserPermanentearelaunchingapilotpr...ionusingtheNationwideHealthInformationNetwork(NHIN..., "Theabilitytosharecriticalhealthinformationis...
Breaking Medicine News(10 mins):Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2Health News:Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California) 2Health News:Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California) 3Health News:VA and Kaiser Permanente Invite Veterans to Participate in Health Record Pilot Program 2
...eople who have the common chronic pain condition f... the types of medication that relieve other people...an Health System helps to explain why that might b...ugs such as morphine. , The study included positr...
...ve Program This Fall for Testing by End of School ..., Texas, Sept. 27 The Texas Education Agency,(TEA...created by The Cooper,Institute and published by H...s a new requirement detailed in Senate,Bill 530 th...
... to Kansas City, Urges Residents to Press,Congress...ican,Medical Association (AMA) National House Call...ents to help press Congress to stop scheduled Medi...,beginning on January 1, 2008., A recent AMA surv...
...t. 27 The National,Legal and Policy Center (NLPC)...t between General Motors (GM) and the United Auto ...alth care in liabilities to a fund,controlled by t...is,a great deal for GM. They get to shed billions ...
...LAGERFELD SAS announced today a,strategic licensin...ARL,LAGERFELD men,s and women,s eyewear starting w...archon, one of the most prominent eyewear companie..."Dark glasses are like portable eye shadow and the...
... 27 Wachovia Bank,N.A., today announced expansion...stry with the addition of PatientPOS(sm), an innov...agement for healthcare,providers. "This solution ...nt and head of Wachovia,s Treasury Services,Payabl...
Other Medicine News:Health News:Why don't painkillers work for people with fibromyalgia? 2Health News:The Cooper Institute's FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool 2Health News:The Cooper Institute's FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool 3Health News:The Cooper Institute's FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool 4Health News:Medicare Cuts to Physicians Will Harm Seniors 2Health News:Medicare Cuts to Physicians Will Harm Seniors 3Health News:KARL LAGERFELD SAS Signs Global Eyewear License Agreement With Marchon Eyewear, Inc. 2Health News:Wachovia Strengthens Its Healthcare Industry Receivables and Cash Management Capabilities 2Health News:Wachovia Strengthens Its Healthcare Industry Receivables and Cash Management Capabilities 3
Max-Rom Acetabular Liners
Cofield 2 Total Shoulder System
Integrated Shoulder System
...index. A/P and lateral fins with holes for suture ...al hole, humeral / glenoid diametral curvature mis...ugh textured proximal surface to provide enhanced ...esistance in cement, six stem sizes, fifteen head ...
Medicine Products: